Article Sidebar

PDF
Date Published: 17/10/2022
Abstract Views: 388
Views PDF: 234
DOI: https://doi.org/10.51298/vmj.v519i1.3564
Issue
Vol. 519 No. 1 (2022)
Section
Các bài báo
How to Cite
Ngọc Đông, P. ., Thị Hương Trà, T. ., & Thị Minh Tuệ, Đặng . (2022). THE RESULTS TREATMENT FOR DRY EYE IN PRIMARY SJÖGREN SYNDROME. Vietnam Medical Journal, 519(1). https://doi.org/10.51298/vmj.v519i1.3564

THE RESULTS TREATMENT FOR DRY EYE IN PRIMARY SJÖGREN SYNDROME

Phạm Ngọc Đông1,2,, Trần Thị Hương Trà1, Đặng Thị Minh Tuệ1
1 Central Eye Hospital
2 University of Medicine and Pharmacy, Vietnam National University, Hanoi

Main Article Content

Abstract

Purpose: Evaluation of the results treatment for dry eye in primary Sjögren Syndrome. Patients and method:  Prospective study carried on 40 eyes of 20 patients with primary SS. The patients have OSDI≥13, TBUT≤10, SSA (+) and/or SSB (+). Collected and analized indicators were OSDI, TBUT, Shirmer I, corneal staining score, conjuntival staining score. Result: We conducted a cross sectional on 40 eyes of 20 patients with primary Sjögren’s syndrome, the results showed that: OSDI decreased significantly after 4 weeks (64.7±14.03; 49.03±14.16), TBUT decreased significantly after 4 weeks (0.7±1.16; 1.58±1.58), conjuntival staining decreased significantly after 2 weeks (10.28±3.42; 8.53±2.92), corneal staining decreased significantly after 2 weeks (12.5±2.41; 11.15±2.27), Schirmer I did not decrease significantly after 8 weeks of treatment. Conclusion: Treatment of dry eye in pSS is limited. The physical anh funtional symtoms improved slowly with the guidline combination of three drugs to treat dry eye (Restasis, Diquas, Cationorm) and systemic treatment. After 8 weeks, only 30% of the treated eyes improved in funtinal symtoms.

Article Details

Keywords

Dry eye, Sjögren’s syndrome

References

1. Craig JP, Nichols KK, Akpek EK, al e. TFOS DEWS II Definition and Classification Report. The ocular surface 2017;15(3):276-283.
2. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983-1989.
3. Bunya VY, Fernandez KB, Ying GS, et al. Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome. Eye & contact lens. 2018;44 Suppl 2(Suppl 2):S196-s201.
4. Kang M-J, Kim Y-H, Chou M, et al. Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren’s Syndrome Dry Eye. Ocular Immunology and Inflammation. 2020;28(3):370-378.
5. Mehmet OZGUR Cubuk, Ahmet Yücel Üçgül, al e. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome. International Ophthalmology. 2021;41:1479-1485.
6. Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (London, England). 2012;26(10):1363-1368.
7. Nguyễn Tiến Đạt. Đánh giá hiệu quả của Diquafosol sodium 3% trong điều trị khô mắt vừa và nặng. Luận văn thạc sĩ y học, Nhãn khoa, Đại học Y Hà Nội. 2017.
8. M. Amrane, C. Creuzot-Garcherb, P.-Y. Robertc, D. Ismaila, al e. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease — A randomised comparative study. Journal français d’ophtalmologie. 2014;37(8):589-598.